Ascendis Pharma A/S’s (ASND) Overweight Rating Reiterated at Cantor Fitzgerald

Posted by Brenda Bartman on Sep 28th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They currently have a $300.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 30.41% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. UBS Group restated a “buy” rating and issued a $344.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, September 16th. Barclays decreased their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday, August 14th. HC Wainwright set a $344.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, Morgan Stanley dropped their price target on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $310.75.

View Our Latest Report on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $4.45 during mid-day trading on Friday, hitting $230.05. The company had a trading volume of 722,817 shares, compared to its average volume of 697,278. Ascendis Pharma A/S has a 12 month low of $186.05 and a 12 month high of $282.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The firm’s 50 day simple moving average is $251.52 and its two-hundred day simple moving average is $242.29. The stock has a market cap of $14.35 billion, a price-to-earnings ratio of 17.85 and a beta of 0.35.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, equities research analysts forecast that Ascendis Pharma A/S will post 3.69 earnings per share for the current year.

Insider Activity at Ascendis Pharma A/S

In other news, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at $810,570. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the acquisition, the director owned 2,900 shares of the company’s stock, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC raised its position in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares during the period. Fred Alger Management LLC boosted its position in Ascendis Pharma A/S by 106.3% during the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock worth $75,084,000 after acquiring an additional 181,408 shares during the period. Pictet Asset Management Holding SA grew its stake in Ascendis Pharma A/S by 243.0% during the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after acquiring an additional 178,415 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter valued at about $26,837,000. Finally, Cormorant Asset Management LP acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $21,324,000.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.